International gathering of experts to share retinoblastoma breakthroughs

February 16, 2005

Experts in the fields of retinoblastoma research and treatment will gather to update colleagues on the latest developments in these fields during a two-day symposium April 28-29 at St. Jude Children's Research Hospital in Memphis.

The symposium, "Retinoblastoma: From Bench to Bedside," will include topics about the treatment of retinoblastoma, the molecular basis of this potentially fatal cancer and new laboratory models to test novel therapies prior to clinical trials. Clinicians will also discuss state-of-the-art therapies for this catastrophic childhood cancer.

Retinoblastoma is the third most common cancer in infants after leukemia and neuroblastoma (nerve cancer). Retinoblastoma that has spread outside the eye is among the deadliest childhood cancers, with an average survival rate of less than 10 percent. Successful treatment of this disease often includes removal of one or both eyes.

The symposium is a watershed event because it occurs at a time of great excitement in the field of retinoblastoma studies, according to Michael A. Dyer, Ph.D., assistant member of St. Jude Developmental Neurobiology. Existing treatments have improved, and breakthroughs have occurred in understanding the molecular signals that drive cells to become cancerous. Also, the recent development of mouse models by Dyer's laboratory and several other laboratories allows St. Jude researchers to test potential new drugs that might be valuable additions to the limited number of agents available to doctors treating children with this cancer.

Previously, mice carrying the mutation in the retinoblastoma (Rb) gene that causes the disease did not survive, since the gene was expressed throughout the body and caused cancer. Dyer's laboratory developed the first mouse model in which the mutation occurs only in the retina, which permitted the use of the model for testing new drugs to treat this cancer.

"This symposium is historic because of the people it brings together at a single site to discuss breakthroughs and state-of-the-art treatments in retinoblastoma," said Dyer, an organizer of the symposium with Carlos Rodriguez-Galindo, M.D. (St. Jude) and Matthew Wilson, M.D. (University of Tennessee Health Sciences Center, Memphis).

Symposium speakers include some of the world's leading researchers, including Alfred G. Knudson Jr., M.D., Ph.D., a senior researcher at the Fox Chase Cancer Center in Philadelphia.

"Dr. Knudson is internationally recognized for his 'two-hit' theory that explains how a cell accumulates mutations before becoming cancerous," Dyer said. "And he predicted the existence of tumor-suppressor genes."

Barrett G. Haik, M.D., (University of Tennessee and chief of Ophthalmology at St. Jude) will make introductory remarks at Thursday morning's opening of the symposium.

Other internationally recognized speakers scheduled for Thursday morning are David Abramson, M.D. (Memorial Sloan-Kettering Cancer Center, New York); Brenda L. Gallie, M.D. (Hospital for Sick Children, University of Toronto); Murali Chintagumpala, M.D. (Baylor College of Medicine, Houston); Manuela A. Orjuela, M.D. (Columbia University, Mailman School of Public Health, New York), and Thomas Merchant, D.O. (St. Jude).

Guillermo Chantada, M.D. (Hospital de Pediatria JP Garrahan, Buenos Aires) will discuss challenges that developing countries face when using limited resources to confront the disease.

The afternoon session, which will focus on mouse models and the genetic basis of retinoblastoma, includes a presentation by Anton Berns, Ph.D. (The Netherlands Cancer Institute), a pioneer in the development of mouse models of human cancers. Other experts in the molecular basis of cancer include Dyer, Rod Bremner (Toronto Western Research Institute), Julien Sage, Ph.D., (Stanford Medical School) and Gerard Zambetti, Ph.D. (St. Jude).

The Friday morning session will include roundtable discussions on future directions of retinoblastoma research, specifically translational research (J. William Harbour, M.D., Washington University School of Medicine, St. Louis) and cooperative studies among institutions (Anna T. Meadows, M.D., Children's Hospital of Philadelphia).
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit

St. Jude Children's Research Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to